Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis

Fig. 3

Plasma-concentration time profiles of anti-IL-6R Nanobodies after a single intravenous administration in cynomolgus monkeys. At day 0, animals received the monovalent non-half-life extended anti-IL-6R domain at 0.74 mg/kg (n = 3) or ALX-0061 at 0.4 (n = 3), two (n = 3), or 10 (n = 2) mg/kg, before daily subcutaneous injection with recombinant hIL-6 at 5 μg/kg for seven consecutive days. Mean (±SD) plasma-concentration time profiles of the Nanobodies are shown on a logarithmic scale. IL-6R: interleukin-6 receptor; SD: standard deviation

Back to article page